[1] Wang Y, Zhu L, Deng H, et al. Quality appraisal of clinical guidelines for venous thromboembolism prophylaxis in patients undergoing hip and knee arthroplasty: a systematic review[J]. BMJ Open,2020,10(12): e40686.
[2] Chinese Orthopedic Association. The Chinese Guideline for Prevention of Venous Thromboembolism after Major Orthopedic Surgery 2016 version [J]. Chin J Orthop, 2016, 36(2):65-71.
[3] Geerts W H, Bergqvist D, Pineo G F, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) [J]. Chest,2008,133(6 Suppl):381S-453S.
[4] Zhang S, Htet K S, Tan X Y, et al. Short-duration chemoprophylaxis might reduce incidence of deep vein thrombosis in Asian patients undergoing total knee arthroplasty[J]. Knee Surgery & Related Research,2020,32(1).
[5] Parvizi J, Ceylan H H, Kucukdurmaz F, et al. Venous Thromboembolism Following Hip and Knee Arthroplasty: The Role of Aspirin[J]. J Bone Joint Surg Am,2017,99(11):961-972.
[6] Warren J A, Sundaram K, Anis H K, et al. Have Venous Thromboembolism Rates Decreased in Total Hip and Knee Arthroplasty? [J]. J Arthroplasty,2020,35(1):259-264.
[7] Pedersen A B, Mehnert F, Sorensen H T, et al. The risk of venous thromboembolism, myocardial infarction, stroke, major bleeding and death in patients undergoing total hip and knee replacement: a 15-year retrospective cohort study of routine clinical practice[J]. Bone Joint J,2014,96-B (4):479-485.
[8] Shahi A, Bradbury T L, Guild G R, et al. What are the incidence and risk factors of in-hospital mortality after venous thromboembolism events in total hip and knee arthroplasty patients? [J]. Arthroplast Today,2018,4(3):343-347.
[9] Bateman D K, Dow R W, Brzezinski A, et al. Correlation of the Caprini Score and Venous Thromboembolism Incidence Following Primary Total Joint Arthroplasty-Results of a Single-Institution Protocol[J]. J Arthroplasty,2017,32(12):3735-3741.
[10] Cassidy M R, Rosenkranz P, Mcaneny D. Reducing postoperative venous thromboembolism complications with a standardized risk-stratified prophylaxis protocol and mobilization program[J]. J Am Coll Surg,2014,218(6):1095-1104.
[11] Alameri M A, Syed Sulaiman S A, Ashour A M, et al. Venous thromboembolism prevention protocol for adapting prophylaxis recommendations to the potential risk post total knee replacement: a randomized controlled trial[J]. Pharmacy Practice,2020,18(3):2025.
[12] Kester B S, Merkow R P, Ju M H, et al. Effect of post-discharge venous thromboembolism on hospital quality comparisons following hip and knee arthroplasty[J]. J Bone Joint Surg Am,2014,96(17):1476-1484.
[13] Venclauskas L, Llau J V, Jenny J Y, et al. European guidelines on perioperative venous thromboembolism prophylaxis: Day surgery and fast-track surgery[J]. Eur J Anaesthesiol,2018,35(2):134-138.
[14] Falck-Ytter Y, Francis C W, Johanson N A, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest,2012,141(2 Suppl):e278S-e325S.
[15] Mont M A, Jacobs J J. AAOS clinical practice guideline: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty[J]. J Am Acad Orthop Surg,2011,19(12):777-778.
[16] Jameson S S, Baker P N, Deehan D J, et al. Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement[J]. Bone Joint Res,2014,3(5):146-149.
[17] Lovett-Carter D, Sayeed Z, Abaab L, et al. Impact of Outpatient Total Joint Replacement on Postoperative Outcomes[J]. Orthop Clin North Am,2018,49(1):35-44.
[18] Turpie A G, Schmidt A C, Kreutz R, et al. Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery[J]. Vasc Health Risk Manag,2012,8:363-370.
[19] Flevas D A, Megaloikonomos P D, Dimopoulos L, et al. Thromboembolism prophylaxis in orthopaedics: an update[J]. EFORT Open Rev,2018,3(4):136-148.
[20] Fuji T, Akagi M, Abe Y, et al. Incidence of venous thromboembolism and bleeding events in patients with lower extremity orthopedic surgery: a retrospective analysis of a Japanese healthcare database[J]. Journal of Orthopaedic Surgery and Research,2017,12(1).
[21] Nagase Y, Yasunaga H, Horiguchi H, et al. Risk factors for pulmonary embolism and the effects of fondaparinux after total hip and knee arthroplasty: a retrospective observational study with use of a national database in Japan[J]. J Bone Joint Surg Am,2011,93(24): e146.
[22] Migita K, Bito S, Nakamura M, et al. Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study[J]. Arthritis Res Ther,2014,16(4): R154.
[23] Le G, Yang C, Zhang M, et al. Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty[J]. Medicine,2020,99(49): e23055.
[24] Xu W, Zhang T, Yang Z, et al. Effect of different types of anticoagulants in the prevention of venous thrombosis in the operation of knee joint bone operation[J]. Pak J Pharm Sci,2018,31(3(Special)):1093-1097.
[25] Kim H A, Lee J Y, Park S H, et al. Clinical outcomes and risk factors of thromboprophylaxis with rivaroxaban versus aspirin in patients undergoing hip arthroplasty in low-incidence population: A nationwide study in Korea[J]. Pharmacoepidemiol Drug Saf,2019,28(4):507-514.
[26] Anderson D R, Dunbar M, Murnaghan J, et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty[J]. N Engl J Med,2018,378(8):699-707.
[27] Husted H, Holm G, Jacobsen S. Predictors of length of stay and patient satisfaction after hip and knee replacement surgery: fast-track experience in 712 patients[J]. Acta Orthop,2008,79(2):168-173.
[28] Scrimenti A, Seabury R W, Miller C D, et al. Pharmacist recommendations for prophylactic enoxaparin monitoring and dose adjustment in trauma patients admitted to a surgical intensive care unit[J]. Pharm Pract (Granada),2019,17(4):1541.